Annovis Bio, Inc. (ANVS), a late-stage clinical drug platform company, on Thursday announced that it has appointed Mark Guerin as Chief Financial Officer.
The appointment is to lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development.
Mark Guerin has extensive experience in managing financial operations. Guerin most recently worked at Onconova Therapeutics, known as Traws Pharma, Inc., where he served as Chief Financial Officer until after its April 2024 merger with Trawsfynydd Therapeutics, Inc.
On Wednesday, Annovis Bio is 1.79% lesser at $2.1900 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.